The market research institute Potentialpark has honored the global healthcare group Fresenius for the 11th consecutive year as the German company with the best overall Internet offering for job applicants.
In Potentialpark’s 2022 study, Fresenius not only took first place in the overall category for all career-relevant online activities, but also won in the individual categories of mobile offering and online application management. Fresenius finished second in the career presence in social media category, and seventh for career website.
Potentialpark has carried out an annual study of German companies’ online offerings for job seekers since 2002. For this year’s study, Potentialpark evaluated the online activities of 140 companies in Germany according to more than 350 criteria. More than 43,000 students and graduates around the world were surveyed about their preferences.
“Digital channels have played a big part in our communications with potential applicants for years, and during the pandemic these digital contact points have become even more important,” said Jennifer Weihs, Head of Corporate Human Resources at Fresenius. “That makes us especially happy about our latest success in the Potentialpark ranking. And in future we aim to continue offering all job seekers the best possible information, as well as a simple online application process.”
The quality of Fresenius’ internet offering has been confirmed in an additional study, by the RheinMain University of Applied Sciences. It analyzed and evaluated the career websites of 138 major German employers, and ranked Fresenius third overall.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
The Eugin Group, part of Fresenius Helios, acquires a majority stake in the Delaware Institute for Reproductive Medicine (DIRM), a renowned fertility center in the U.S. state of Delaware that has been established for 35 years. With this acquisition, Eugin further expands its existing network in the U.S. and expects to generate additional synergies and operational efficiencies. A number of key physicians will remain minority shareholders in DIRM. Both sides have agreed not to disclose financial details.
In this year's ranking, the non-profit organization CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 590 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.
In this year's ranking, the non-profit organization CDP has confirmed Fresenius Medical Care' classification. The company was again listed in the second highest categories B in the area climate and B- in the area water. Fresenius Medical Care is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 590 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced changes to the Management Board effective on January 1, 2022. They follow a unanimous decision by the Supervisory Board of Fresenius Medical Care Management AG to adapt the composition of the Management Board to the company’s new operating model, which is being launched in 2023.
The new, globally operating Care Delivery segment, in which the company is combining its global healthcare services business, will be led by William Valle (61), currently CEO of Fresenius Medical Care North America. Dr. Katarzyna Mazur-Hofsäß (58), currently CEO of the Europe, Middle East and Africa (EMEA) region, will take over responsibility for the new, globally operating Care Enablement segment, in which Fresenius Medical Care is consolidating its previously decentralized healthcare products business under a global MedTech umbrella.
Rice Powell (66) will continue to serve as Fresenius Medical Care’s CEO, and the Global Medical Office will continue to be led by Franklin W. Maddux, MD (64). Chief Financial Officer Helen Giza (53) will be taking on the additional role of Chief Transformation Officer.
Harry de Wit (59), CEO for Asia-Pacific, Kent Wanzek (62), CEO for Global Manufacturing, Quality and Supply (GMQS), and Dr. Olaf Schermeier (49), CEO for Global Research and Development, will move from the Fresenius Medical Care Management Board to the Fresenius Medical Care Executive Committee.
During the transition phase, Harry de Wit will continue leading the business in the Asia-Pacific region and take on additional responsibility for EMEA. Kent Wanzek will continue to have responsibility for GMQS, with a focus on the full transition of its activities into the new Care Enablement organization. Dr. Olaf Schermeier will take over the leadership of the Critical Care business and Fresenius Medical Care Ventures, two of the company’s most important growth areas within the Care Enablement segment. All three will be reporting to Dr. Katarzyna Mazur-Hofsäß. In 2022, the current country organizations will be mapped, and will subsequently be transitioned to the new operating model.
Stephan Sturm, Chairman of the Supervisory Board of Fresenius Medical Care Management AG, said: “The Supervisory Board fully supports the upcoming reorganization as it will strengthen Fresenius Medical Care and lay the foundations for the company’s continued, successful development. Our special thanks and respect go to Harry de Wit, Kent Wanzek and Olaf Schermeier. They have made valuable contributions on the Management Board over the years, and now stand ready to assume responsibility in new roles. On behalf of the Supervisory Board, I wish the entire management team and our employees every success, as we build new and robust organizational structures that will stand the test of time.”
Rice Powell, CEO of Fresenius Medical Care, said: “2022 will be a significant year of transition as we move toward our new operating model as a leaner, and at the same time stronger, basis for executing our growth strategy. I look forward to the continued cooperation with our leadership team and all Fresenius Medical Care colleagues. It is a lot of work to make this work, but I’m sure that with the new operating model and the resulting changes we are setting the course for a successful future for Fresenius Medical Care – for the benefit of all the company’s stakeholders.”
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed agreements to acquire Centro Oncológico de Antioquia (COA) and Clínica Clofán, further expanding the company’s presence in Colombia. The clinics, located in Colombia's second largest city Medellín, will become part of Quirónsalud’s existing healthcare network in the country, which already comprises six hospitals and ten diagnostic centers.
COA is specialized in the diagnosis and treatment of cancer. It has 75 beds, four operating rooms, and specialized centers for nuclear medicine, radiotherapy and bone marrow transplants. Clínica Clofán is the second largest ophthalmic center in the city, with ten operating rooms and further dedicated facilities for treating even severe ophthalmic diseases and performing complex procedures.
Both clinics offer state-of-the-art medical standards and technology to their patients and are regarded as leading medical facilities with highly renowned physicians. Together they generate sales of around €30 million.
The acquisition is another important step in strengthening Fresenius Helios’ presence in the growing and consolidating healthcare services markets in Latin America.
The transaction is expected to close in the first quarter of 2022, pending anti-trust clearance of the Colombian authorities. Fresenius Helios expects the acquisition to be accretive to Fresenius’ Group net income* already in fiscal year 2022.
*Net income attributable to shareholders of Fresenius SE & Co. KGaA
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, has been recognized for the 12th time as a sustainability leader, with inclusion in the Dow Jones Sustainability Index. The DJSI Europe is composed of the top 20 percent of the largest 600 European companies listed in the S&P Global BMI, based on the international investment company S&P Global’s analysis of their economic, environmental and social performance. Fresenius Medical Care achieved improvements in most categories and was awarded maximum scores for partnerships toward sustainable healthcare, environmental reporting and social reporting. The company’s scores also rose significantly in the areas of risk management and customer relationship management.
Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent based on the international investment company S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Cybersecurity, Data Protection and Human Rights. In the area of Partnerships towards sustainable healthcare, Fresenius was awarded the maximum score in the rating 2021.
- Globalization of operating model to leverage expertise, capture growth opportunities and accelerate value creation
- Business operations to be structured in two global operating segments: Care Enablement and Care Delivery
- Reduction of annual cost base of EUR 500 million by 2025 with anticipated one-time investments of around EUR 450-500 million
- First year of net savings expected in 2023
Fresenius Medical Care continues to execute on its growth strategy 2025 launched in October 2020. The world's leading provider of products and services for individuals with renal diseases today announced the next phase of its transformation program FME25 – the transformation of its operating model – to provide the base for future sustainable growth. With a significantly simplified future structure of two global operating segments – Care Enablement and Care Delivery – Fresenius Medical Care orients its operating model along the relevant future value drivers. With greater cost efficiency and a superior ability to capture additional growth opportunities, the aim of the new, leaner structure is also to mitigate the ongoing negative effects of COVID-19 as well as the challenging macroeconomic environment with inflationary trends. Fresenius Medical Care expects to complete the roll-out of its new global operating model around 2023 and the savings initiative largely completed by 2024.
Rice Powell, CEO of Fresenius Medical Care, said: “FME25 is about taking our value creation to the next level. Over the past months, we have worked with dedication on our plans for a fundamental transformation of our Company. In this process, I have seen great commitment to making Fresenius Medical Care more agile, leverage expertise, accelerate innovation and further optimize capital allocation. Helen Giza, our CFO, will also assume the role of Chief Transformation Officer and lead the global efforts on FME25. While FME25 will change the way we operate in the future, our new global operating model is deeply grounded in our longstanding vision to improve the quality of outcomes for our patients. I am convinced that we will be able to live up to this joint purpose even better in our new structure and at the same time further strengthen our long-term profitable growth.”
Globalization of Operating Segments and support functions
The new simplified operating model is the continuation of the plan to globalize and simplify as a part of the implementation of the 2025 growth strategy. It is designed to further leverage the advantages of the Company’s vertical integration, to better capture identified growth opportunities, leverage expertise to accelerate value creation, enhance capital allocation, increase transparency both internally and externally, reduce administrative burden as it relates to cost and speed, and to advance a culture of agility, innovation and accountability.
In the new model the Company will manage its business in two global operating segments, adopting a more centralized approach:
In Care Enablement, Fresenius Medical Care is consolidating its previously decentralized healthcare products business including research and development, manufacturing, supply chain and commercial operations as well as supporting functions, such as regulatory and quality management under a global MedTech umbrella. The products business will be organized along the three treatment modalities that the Company is serving: In-center, Home and Critical Care. This structure has the benefit of reduced organizational complexity and in turn increased accountability and agility in decision making and bringing innovative products to market. Pro-forma, Care Enablement represents around 20% of the Company´s financial year 2020 revenues.
Fresenius Medical Care’s global healthcare services business will be combined in the Care Delivery segment. In doing so, Fresenius Medical Care aims to leverage its scale, capabilities, technologies and best practices globally and its world-leading expertise in the field of value-based care to address new patient groups in the U.S. and in other geographies. The new globalized structure enables a strategic review of all services markets and an enhancement of the cost structure to deliver on the Company´s sustainable profitable growth aspirations. Pro-forma, Care Delivery represents around 80% of the Company´s financial year 2020 revenues.
The Global Medical Office continues to leverage the vertically integrated approach to achieve the best clinical outcomes for our patients, their families and the payor community by evaluating coordinated data from clinical science research and medical practice on a global basis to improve treatment outcomes.
The new global operating model will enable the further consolidation of General and Administrative functions. A three pillars model of business partnering, centers of excellence and global shared services will be applied. This will allow for reduction of organizational complexity and streamlining processes while driving efficiency via digitalization and standardization. While the globalization of Finance, IT and Procurement is already underway, the Company will apply the same model to Human Resources, Legal and Compliance, which are currently regionalized.
Sustainable cost reduction by EUR 500 million
Based on the implementation of the new global operating model, Fresenius Medical Care assumes to reduce its annual cost base by EUR 500 million by the end of 2025.
Helen Giza, CFO and CTO of Fresenius Medical Care, said: “We are excited about the identified value creation opportunity for the Company. Due to the extensive work and progress over the last months, we already have clear line of sight into EUR 400-450 million with further initiatives under review.”
Around 50% of these savings are expected to be realized by 2023. By the end of 2023 around 80% of the anticipated one-time investments in FME25, amounting to approximately EUR 450-500 million, are expected to be made. The investments will be treated as a special item. The Company thus expects to reach positive net savings by the end of 2023.
Fresenius Medical Care anticipates reducing up to 5,000 full-time equivalents worldwide as part of the FME25 program. The Company is committed to implementing necessary changes in a socially responsible way, and to following applicable consultation procedures with works councils and other workplace representative bodies in good faith.
Conference call
Fresenius Medical Care will host a two hours conference call to discuss the results of the third quarter and first nine months of 2021 on November 2, 2021 at 3:30 p.m. CET / 10:30 a.m. EDT. Please note that this will be an extended call, as the Company will additionally provide an update on the FME25 transformation program. Details will be available on the Fresenius Medical Care website www.freseniusmedicalcare.com in the “Investors” section. A replay will be available shortly after the call.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.